Safety and Efficacy of PTH-IA for Rare Genetic Bone Disorder
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This trial tests a new medication called PTH-IA for people with a specific genetic mutation affecting the parathyroid hormone receptor. The study aims to see if the medication is safe and can help improve bone health in children and adults with this rare condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific genetic mutation in the PTHIR gene (one of: H223R, I458K, I458R, T410P, or T410R)
- You must weigh at least 35 kg (77 lbs) if in the adult group, or 18 kg (40 lbs) if in the child group
- You must have adequate kidney function and liver function based on blood tests
- You must have normal vitamin D levels and adequate hemoglobin (red blood cell count)
- If you can become pregnant, you must use effective birth control during the study
- You must be able to travel to the NIH Clinical Center and commit to all study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that follows people who have or may develop parathyroid-related conditions. The goal is to better understand how these problems change over time and what patterns show up, which can help improve future care.
This study tests a new medicine called palopegteriparatide for teenagers with long-term hypoparathyroidism (low parathyroid hormone). The medicine is given as a daily injection and aims to help control calcium levels.
This early study looks at how the body’s handling of phosphate may affect aging and bone health. It is meant for people with certain rare genetic conditions that change phosphate levels, to better understand their biology and responses to study tests.
This trial tests a new drug called AGA2115 for people with osteogenesis imperfecta (also known as brittle bone disease) who have a confirmed genetic change in the COL1A1 or COL1A2 genes. The study aims to see if the drug can help strengthen bones and reduce fracture risk.
This trial tests an experimental drug called Canvuparatide against a placebo to see if it can help adults with a condition called hypoparathyroidism, where the body doesn't make enough parathyroid hormone. The goal is to improve calcium levels and reduce the need for high-dose calcium and vitamin D supplements.
This trial tests whether mesenchymal stem cells (special cells that can become bone) can help children with severe osteogenesis imperfecta (brittle bone disease) by improving bone strength and growth. It is for children aged 3 to 9 who have a confirmed gene change and have already been treated with pamidronate for at least a year.
Hear when a new Jansen's Metaphyseal Chondrodysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.